Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 ...
The 60-minute live case study walkthrough will reveal how a leading global CRO used Ryght's AI-powered platform to complete a process that traditionally takes 6+ months in just 26 days, while ...
The CRO selection follows a series of groundbreaking preclinical results announced in recent months, including SIL204's demonstrated efficacy across pancreatic, colorectal, and lung cancer models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results